Referencing for people who value simplicity, privacy, and speed.Get Citationsy
← Back to Search
Viral Xenogenization Of Intact Tumor Cells.
Published 1979 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Publisher Summary Tumor immunotherapy modifies tumor cells so that they become more foreign to the host. This chapter explores the ways investigators have attempted to make tumor cells foreign to the host by increasing their antigenicity. It reviews attempts to induce new foreign proteins on tumor cells and to increase the antigenicity of existing tumor-specific or tumor-associated antigens (TSA or TAA) on tumor cells. By both of these methods tumor cells can be made more highly immunogenic or more easily immunosensitive to the immune responses of the host. Tumor cells show low antigenicity and are not readily recognized as foreign by the host. By the process of xenogenization of tumor cells infected with a nonlytic budding murine virus, the regression of tumors is caused when inoculated into normal hosts owing to an acquisition of virus-specific antigen that is foreign in the host. Xenogenization is used to describe the process of making a tumor cell antigenically foreign to the host. Studies performed on tumor cells that have been infected with a nonlytic budding virus are summarized in the chapter. It also discusses the acquisition of a virus-specific new antigen in tumor cells.
This paper references
Immunity and tolerance in oncogenesis.
L. Severi (1969)
[Acute myelogenous leukemia: trial therapy with a myxovirus adapted to myeloblasts].
C. Sauter (1972)
Immune responses in mice to tumour challenge after immunization with newcastle disease virus‐infected or X‐irradiated tumour cells or cell fractions
P. Beverley (1973)
Contribution of antiviral immunity to oncolysis by Newcastle disease virus in a murine lymphoma.
M. Eaton (1967)
Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice
P. Lachmann (1978)
Augmented immunogenicity of tumor cell homogenates infected with influenza virus.
C. Boone (1972)
Demonstration of Graffi leukemia virus and virus-induced antigens in leukemic and nonleukemic tissues of mice.
G. Pasternak (1967)
Correlation between concanavalin A agglutinability and cytotoxic sensitivity to antiserum against tumor-associated antigen in rat fibrosarcoma cells.
T. Moriuchi (1979)
Enhancement of lymphoma cell immunogenicity by infection with nononcogenic virus.
M. Eaton (1973)
Immune enhancement of the tumorigenicity of hamster brain tumor cells persistently infected with measles virus
J. Evermann (1975)
Inhibition of metastasis in rats immunized with xenogenized autologous tumor cells after excision of the primary tumor.
H. Kobayashi (1975)
Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution.
G. Klein (1977)
AN APPARENT HISTOINCOMPATIBILITY BETWEEN MICE CHRONICALLY INFECTED WITH LYMPHOCYTIC CHORIOMENINGITIS VIRUS AND THEIR UNINFECTED SYNGENEIC COUNTERPARTS
O. Holtermann (1971)
Xenogenization of Tumor Cells
小林 博 (1977)
Modification in growth of transplantable rat tumors exposed to Friend virus.
H. Kobayashi (1969)
Augmented immunogenicity of tumor cell membranes produced by infection with influenza virus as compared to Moloney sarcoma virus.
N. Takeichi (1978)
Infection of human embryonic cell cultures with the Rauscher murine leukemia virus.
B. Wright (1969)
On the possibility of intercalation of aromatic amino acid residues into double-stranded DNA helix
John R. Jacobsen (1974)
Cell surface antigens detectable by cytotoxic test on Friend virus-induced and Friend virus-infected tumors in the rat.
T. Shirai (1971)
Observations with a variant of lymphocytic choriomeningitis virus in mouse tumors.
J. Eiselein (1970)
Decrease in tumor‐producing capacity of mouse cell lines following infection with mouse leukemia viruses
D. Barbieri (1971)
Artificial Heterogenization of Tumours by means of Herpes Simplex and Polyoma Viruses
V. Hamburg (1964)
Virus‐augmented tumor transplantation antigens: Evidence for a helper antigen mechanism
C. Boone (1974)
Combination of active and passive immunization and chemotherapy to transplantation of methylcholanthrene-induced tumor in WKA rats.
E. Gotoda (1974)
Quantitative Relationships in Viral Oncolysis and the Possibility of Artificial Heterogenization of Tumours
G. J. Svet-Moldavsky (1964)
Change of antigenic expression on rat tumor cells after their transplantation.
E. Gotohda (1975)
Increased immunogenicity of low‐antigenic rat tumors after superinfection with endogenous murine C‐type virus in nude mice
N. Kuzumaki (1978)
REDUCED TRANSPLANTABILITY OF SYNGENIC MOUSE TUMORS SUPERINFECTED WITH MEMBRANE VIRUSES IN NU/NU MICE
N. Kuzumaki (1976)
VIRAL ONCOLYSIS: INCREASED IMMUNOGENICITY OF HOST CELL ANTIGEN ASSOCIATED WITH INFLUENZA VIRUS
J. Lindenmann (1967)
Immunological study of two stocks of moloney sarcoma virus producing regressor and progressor tumors in C57BL/6 mice
N. Takeichi (1978)
In vivo inoculation of RNA C-type viruses inducing regression of experimental solid tumors.
J. Greenberger (1973)
Histopathology of immunologic regresssion of tumor metastasis in the lymph nodes.
T. Kodama (1974)
Induction of polyoma specific transplantation antigenicity in Moloney leukemia cells.
H. Sjögren (1965)
Viral oncolysate in the management of malignant melanoma. II. Clinical studies
D. Murray (1977)
Inhibition of transplanted rat tumors by immunization with identical tumor cells infected with Friend virus.
H. Kobayashi (1970)
Antigenic Conversion of Established Leukæmias by an Unrelated Leukæmogenic Virus
B. Stück (1964)
This paper is referenced by
Melanoma with Allogeneic Cell Lysates
MALCOLM S. MITCHELL (2006)
Antigenic variation in cancer metastasis: immune escape versus immune control
V. Schirrmacher (2004)
Effective anti‐metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with newcastle disease virus (NDV)
D. Plaksin (1994)
Augmented immunogenicity of Lewis lung carcinoma by infection with herpes simplex virus type 2.
R. Reiss-Gutfreund (1982)
Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: Diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2
F. Okada (2005)
Genetically engineered HSV in the treatment of glioma: a review
J. Markert (2000)
Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis
A. Van Pel (1983)
CHAPTER 3 – SPONTANEOUS REGRESSION OF XENOGENIZED TUMOR METASTASIS IN RATS
H. Kobayashi (1985)
Chemotherapy for melanoma: the resultant of conflicting vectors.
M. Mitchell (2004)
Biotherapy of cancer
V. Schirrmacher (2005)
Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates Rationale, Results, and Possible Mechanisms of Action a
M. Mitchell (1993)
Progression of a Weakly Tumorigenic Mouse Fibrosarcoma at the Site of Early Phase of Inflammation Caused by Plastic Plates
F. Okada (1993)
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
V. Schirrmacher (2016)
Association of HLA phenotype with response to active specific immunotherapy of melanoma.
M. Mitchell (1992)
N. Riedel (1989)
Immunological regression of metastatic cancer in the liver as a result of “in vivo xenogenization”
Y. Suzuki (1990)
Viral oncolysates as human tumor vaccines.
J. Sinkovics (1991)
Viral oncolytic immunotherapy in the war on cancer: Infection control considerations
E. Robilotti (2019)
Exploiting Viruses to Treat Diseases.
Dan L. Longo (2018)
Susceptibility of Marek's disease lymphoblastoid cell lines to infection with influenza and pseudorabies viruses and the protective effect of immunization with influenza virus-infected lymphoblastoid cells
L. Ross (2005)
Experimental Therapy for Malignant Brain Tumors Using Genetically Engineered Herpes Simplex Virus Type 1
Toshihiro Mineta (1996)
Modification of tumor cells by a low dose of Newcastle disease virus
H. Schild (2004)
Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene.
E. Fearon (1988)
Virus augmentation of the antigenicity of tumor cell extracts.
F. C. Austin (1979)
Chemical xenogenization of experimental tumors
P. Puccetti (2004)
Development of highly immunogenic variants of a rat fibrosarcoma line during in vitro cultivation
K. Yamashina (2004)
Tumor specific antigens induced by mutagens and DNA hypomethylating agents: implications for the immunobiology of neoplasia
R. Kerbel (1986)
Systemic immunity against a murine colon tumor (CT‐26) produced by immunization with syngeneic cells expressing a transfected viral gene product
H. Schackert (1989)
Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation.
S. Peppoloni (1985)
Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
V. Schirrmacher (1997)
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity
V. Schirrmacher (2004)See more